GOVX GeoVax Labs, Inc.
Listings ·
GeoVax can borrow up to $1,000,000 at 12% interest from Bowery Consulting Group, and it agreed to pursue a public offering of at least $5,000,000. The lender designated the new directors.
The board will pick a reverse split ratio between 1-for-10 and 1-for-25. Holders also approved up to 11,395,256 shares for warrants issued in August 2026, against 9,093,871 shares outstanding at the record date.
GeoVax missed the March 31, 2026 deadline for its 2025 annual report and expects to file within 15 days. It expects a 2025 net loss of about $21.5 million, and its 2024 annual report carried a going-concern warning from the auditors.
GeoVax sold 402,000 shares and pre-funded warrants for up to 30,902 shares, plus Series A-1 and A-2 warrants in a concurrent private placement. H.C. Wainwright & Co., LLC was placement agent.
GeoVax's closing bid price was below $1.00 for 30 consecutive business days, according to a July 31, 2025 deficiency letter. The first deadline is January 27, 2026, and a second 180-day period is possible.
Each unit carried one share and two warrants exercisable at $0.65. Estimated net proceeds are $5,582,557.50, and the lead program is a COVID-19 vaccine whose key comparison trial is still ahead.
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers, using novel proprietary platforms. Its primary near-term strategic development priority is GEO-MVA, a Modified Vaccinia Ankara vaccine candidate for mpox, smallpox and other poxviruses, which is advancing on an expedited regulatory pathway in Europe. The company plans to initiate a pivotal Phase 3 trial in the second half of 2026 and says GEO-MVA is intended to address a significant global supply constraint for orthopoxvirus vaccines. Its lead clinical oncology program, Gedeptin, is an oncolytic solid tumor gene-directed therapy that recently completed a multicenter Phase 1/2 trial for advanced head and neck cancers. A Phase 2 trial combining Gedeptin with an immune checkpoint inhibitor is planned to start in the first half of 2027. GeoVax is also developing GEO-CM04S1, a multi-antigen COVID-19 vaccine evaluated in Phase 2 trials, including as a primary vaccine for immunocompromised patients and as a booster in patients with chronic lymphocytic leukemia. The company holds NIH rights covering preclinical, clinical and commercial uses of NIH-MVA against mpox and smallpox.
| Product or program | What it is | Stage |
|---|---|---|
| GEO-MVA | Modified Vaccinia Ankara vaccine candidate for mpox and smallpox | Phase 3 initiation planned for H2 2026 |
| Gedeptin | Oncolytic solid tumor gene-directed therapy for head and neck cancers | Phase 1/2 completed |
| GEO-CM04S1 | Multi-antigen next-generation COVID-19 vaccine | Phase 2 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $18.1 million | $23.7 million |
| Net income (loss) | -$21.5 million | -$25.0 million |
| Cash from operations | -$21.5 million | -$24.7 million |
| Cash and equivalents | $3.1 million | $5.5 million |
Our latest story on this, dated Oct 27, 2026: "GeoVax stockholders approve reverse split of up to 1-for-25 and warrant share issuance". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 31, 2026: "GeoVax Labs files NT 10-K, says 2025 annual report will be late". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 27, 2026: "GeoVax signs $1,000,000 credit line as five directors make way for lender nominees". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 1, 2025: "GeoVax receives Nasdaq bid price deficiency notice, has until January 27, 2026". The story links the filing or release it is based on. Read the story.
GeoVax Labs, Inc. trades under the ticker GOVX on NASDAQ.
GeoVax Labs, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for GeoVax Labs, Inc. is 832489. Its filings are on SEC EDGAR.
7,369,243 shares as of 2026-07-27, per the cover page of its 10-Q filed 2026-07-27.
Our directory records GeoVax Labs, Inc. under United States.
Our directory classifies GeoVax Labs, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for GeoVax Labs, Inc. is US3736787058.
aibio.space lists GeoVax Labs, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers, using novel proprietary platforms. Its primary near-term strategic development priority is GEO-MVA, a Modified Vaccinia Ankara vaccine candidate for mpox, smallpox and other poxviruses, which is advancing on an expedited regulatory pathway in Europe.
GEO-MVA: Modified Vaccinia Ankara vaccine candidate for mpox and smallpox Stage: Phase 3 initiation planned for H2 2026.
Reported a reverse stock split. SEC Form 8-K (Items 1.01,2.03,3.03,5.02,7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
Reported a financing. SEC Form S-1. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported a financing. SEC Form 424B4. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio